Disseminated histoplasmosis presenting with oral lesions - report of a case

Treating Oral Histoplasmosis in an Immunocompetent Patient

“…5 Oral lesions have been reported in 25 to 45 percent of patients with documented cases of progressive disseminated histoplasmosis and in several case reports. [6][7][8][9] In endemic areas, H. capsulatum is a major opportunistic pathogen in patients infected with the human immunodeficiency virus (HIV); approximately 5 percent of patients with AIDS in these areas develop disseminated histoplasmosis. 10 In immunocompetent hosts, few cases of oral histoplasmosis without detectable systemic involvement have been described.…”

“…10 In immunocompetent hosts, few cases of oral histoplasmosis without detectable systemic involvement have been described. 7,11 Oral histoplasmosis may manifest at any region of the mouth as nodules, deep ulcerative or vegetative lesions or painful shallow lesions. 11,12 The clinician usually makes a definitive diagnosis by using a combination of methods, including culture, detection of H. capsulatum in tissues, quantification of antibodies and/or detection of antigens.…”

Granulomatous Hepatitis Secondary toHistoplasmaInfection after Treatment with Infliximab

“…Histoplasmosis caused by HC is found worldwide. In the United States of America (USA) it is the most common systemic mycosis [ 12 ] and is recognized as an important reason for respiratory infections in endemic areas, particularly temperate regions in USA and in South America. In this scene HI has to be considered in every immunosuppressed patient, especially when, nowadays, more than 400 000 patients with RA, inflammatory bowel disease, psoriatic arthritis, and ankylosing spondylitis are treated with anti-TNF α therapy and since its approval by FDA worries related to its safety appeared, mainly related to reactivation of granulomatous diseases (tuberculosis) [ 2 ].…”

“…In this scene HI has to be considered in every immunosuppressed patient, especially when, nowadays, more than 400 000 patients with RA, inflammatory bowel disease, psoriatic arthritis, and ankylosing spondylitis are treated with anti-TNF α therapy and since its approval by FDA worries related to its safety appeared, mainly related to reactivation of granulomatous diseases (tuberculosis) [ 2 ]. However it is not clear if the latent primary infection represents risk of endogenous reactivation after the use of anti-TNF α [ 12 ].…”

Reactivation histoplasmosis after treatment with anti-tumor necrosis factor α in a patient from a nonendemic area

“…Anti-TNF-a therapy was held and the patient responded well to itraconazole therapy. [1][2][3] Discussion HC is a soil fungus endogenous to the southeastern US, mid-Atlantic States, and the Ohio and Mississippi River Valleys. 4 Primary infection with HC is usually subclinical or self-limited but may present as a fulminant infection in immunocompromised patients.…”